Marker Therapeutics Awarded $2.6M FDA Grant for Pancreatic Cancer Therapy

Key Facts

1Marker Therapeutics was awarded a $2.6 million grant from the U.S. FDA to advance its MT-601 therapy for pancreatic cancer.

Marker Therapeutics was awarded a $2.6 million grant from the U.S. Food and Drug Administration (FDA) to advance its MT-601 therapy for pancreatic cancer. GlobeNewswire reported that the funding, provided through the FDA’s Orphan Products Clinical Trials Grants program, will support a Phase 1 clinical study evaluating the investigational T cell therapy in patients with locally advanced unresectable disease.

MRKR closed at $1.04 on October 16, 2026, having traded between a low of $1 and a high of $1.2 during that session. The MT-601 therapy targets six different tumor antigens, and the company has previously secured non-dilutive funding from the National Institutes of Health (NIH) and the Cancer Prevention and Research Institute of Texas to support its pancreatic cancer program.